Posts Archive

First Posted 2018-07-03 Trial status Active, not recruiting Sponsor Groupe Oncologie Radiotherapie Tete et Cou Abstract Presentation NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Meeting Abstract: 2025 ASCO Annual Meeting II Head and Neck Cancer - June 04, 2025 Click here for details Press Release GORTEC Announces New Trial Suc

First Posted 2020-01-09 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.   Meeting Abstract: 2025 ASCO Annual Meeting II June 04, 2025 Click here for details LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervic

First Posted 2017-03-27 Trial status Active, not recruiting Sponsor Sarcoma Alliance for Research through Collaboration Abstract Presentation Meeting Abstract: 2024 ASCO Annual Meeting Sarcoma - May 29, 2024 SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma. Click here for details Peer-reviewed journal publication THE LANCET Volume 404, Issue 10467p2053-2064November 23, 2024 Safety and efficacy of pembrolizuma

First Posted 2018-08-17 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. June 3, 2023 2023 ASCO Annual Meeting Click here for details Peer-reviewed journal publication Pembrolizumab for Persistent, Recurrent, or Metastati